Verapamil Benefits Chronic Rhinosinusitis With Nasal Polyps

Share this content:
Verapamil Benefits Chronic Rhinosinusitis With Nasal Polyps
Verapamil Benefits Chronic Rhinosinusitis With Nasal Polyps

THURSDAY, Jan. 26, 2017 (HealthDay News) -- For patients with chronic rhinosinusitis with nasal polyps (CRSwNP), the first-generation inhibitor of epithelial P-glycoprotein (P-gp; an efflux pump that is overexpressed in CRSwNP), verapamil hydrochloride (HCl), is associated with improvement in outcome measures, according to a letter to the editor study published online Jan. 23 in the Journal of Allergy and Clinical Immunology.

Marcel M. Miyake, M.D., from Harvard Medical School in Boston, and colleagues conducted a randomized placebo-controlled trial comparing oral verapamil HCl to placebo over eight weeks. Patients were followed up at weeks two, four, and eight. Eighteen patients completed the study: 10 from the verapamil group and eight from the placebo group.

The researchers found that from baseline to week eight, the least squares mean change in the validated disease-specific 22-item Sinonasal Outcome Test was −27.3 and 0.4 in the verapamil and placebo groups, respectively, resulting in a final difference between the groups of −27.7 (P = 0.01). The final least squares mean between-group difference in visual analogue scale score was −37.97 (P = 0.001). There was a significant difference favoring the verapamil group in the Lund-Mackay computed tomography score (absolute mean difference, −5.20; P = 0.02). The verapamil group also had a significant reduction in total Lund-Kennedy endoscopic score at week four (least mean squares difference of −2.8 between the groups; P = 0.003).

"Our data demonstrate that low-dose verapamil monotherapy is well tolerated by patients, with [fewer] side effects and lower costs than those reported in previous studies using biologic agents," the authors write.

Several authors disclosed financial ties to medical technology companies; one author provided expert testimony on ENT-related cases, and has a patent for P-gp inhibition for chronic rhinosinusitis.

Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions

More in Home

FDA Approves New Parkinson's Add-On Drug Xadago

FDA Approves New Parkinson's Add-On Drug Xadago

To help prevent 'off' episodes among users of levodopa/carbidopa

Infant Mortality Down in United States From 2005 to 2014

Infant Mortality Down in United States From 2005 ...

Largest decreases seen for infants of Asian or Pacific Islander and non-Hispanic black women

Intensive Strategy Addresses Hypoxemia After Cardiac Surgery

Intensive Strategy Addresses Hypoxemia After Cardiac Surgery

Intensive alveolar recruitment strategy linked to less severe pulmonary complications after cardiac sx

is free, fast, and customized just for you!

Already a member?

Sign In Now »